GeneSight Testing in Omaha


Are You Struggling to Find the Right Medication?

If you’ve been diagnosed with depression and failed at least one medication, you may benefit from GeneSight® Testing.  GeneSight testing takes the guesswork out of predicting patients’ vulnerability to experiencing specific types of reactions from specific medications.


Are You Ready to Find Answers?

About GeneSight® Testing

GeneSight is a laboratory developed genetic test that looks at many of the genes involved when your body processes certain types of medicines.

The GeneSight test analyzes how your DNA may affect your response to depression medications. The results of the test can help your doctor prescribe a more genetically optimal medication and avoid medications that may cause side effects or be less likely to work. ​

GeneSight is the only genetic test that provides this combined view to help your healthcare provider know which medicines may be a match for your genes. GeneSight gives your healthcare provider important information to help you get on the right medicine.

Multiple clinical studies have shown that when healthcare providers used GeneSight to help guide treatment decisions, patients were twice as likely to respond to the selected medication. Plus, with treatment guided by GeneSight, patients saw a 70% greater improvement in their symptoms versus usual treatment.1

Many commercial and government insurance plans, including Medicare and the U.S. Department of Veterans Affairs, reimburse all or part of the cost of GeneSight. Assurex Health also offers financial assistance programs for patients who qualify.


Counseling Connections & Associates' GeneSight Providers:


For more information, visit their website:

Customer Service


1. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics. 2013;23(10):535-548.